Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples